INmune Bio
INMB
36 hedge funds and large institutions have $17.4M invested in INmune Bio in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
56% more call options, than puts
Call options by funds: $645K | Put options by funds: $413K
6% more funds holding
Funds holding: 34 → 36 (+2)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
1.64% less ownership
Funds ownership: 12.86% → 11.23% (-1.6%)
9% less capital invested
Capital invested by funds: $19.1M → $17.4M (-$1.72M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$239K |
| 2 |
SC
Sepio Capital
Salt Lake City,
Utah
|
+$164K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$112K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$79.6K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$70.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$686K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$568K |
| 3 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
-$521K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$387K |
| 5 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$368K |
INMB Hedge Fund Activity: Q2 2022 in Review
36 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q2 2022, worth a combined $17.4M — down 9% from $19.1M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new INMB positions and 3 closed out — a net gain of 2 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $239K. The largest seller was Morgan Stanley, cutting an estimated $686K.
- 36 institutional investors held INmune Bio (INMB) as of Q2 2022, up from 34 in Q1 2022.
- Funds reported $17.4M of INmune Bio stock for Q2 2022, down 9% quarter-over-quarter.
- 5 funds opened new INmune Bio positions in Q2 2022 and 3 closed out, a net change of +2 holders.
- The largest INmune Bio buyer in Q2 2022 was Renaissance Technologies, an estimated $239K added.
- The largest INmune Bio seller in Q2 2022 was Morgan Stanley, an estimated $686K sold.
Based on aggregated 13F filings for Q2 2022.